Jonathan Anderman Buys 20,000 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) insider Jonathan Anderman acquired 20,000 shares of the firm's stock in a transaction on Monday, April 7th. The stock was purchased at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now directly owns 21,000 shares in the company, valued at $32,340. This represents a 2,000.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Compass Therapeutics Stock Up 2.7 %

NASDAQ:CMPX traded up $0.05 on Friday, reaching $1.70. The company's stock had a trading volume of 650,759 shares, compared to its average volume of 856,142. Compass Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $4.08. The stock has a 50 day moving average price of $2.56 and a 200 day moving average price of $2.10. The firm has a market cap of $234.39 million, a price-to-earnings ratio of -4.58 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently made changes to their positions in the stock. Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at $11,293,000. Tang Capital Management LLC increased its stake in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after purchasing an additional 4,087,005 shares during the period. MPM Bioimpact LLC lifted its position in shares of Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after purchasing an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after purchasing an additional 356,352 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after buying an additional 227,864 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.

Analyst Upgrades and Downgrades

CMPX has been the topic of several research reports. Wedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $12.00 price target on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target for the company. Finally, Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $13.38.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.